Mesenchymal Stromal Cells as Reprogramming Source for iPSC Induction

The USPTO issued Patent US12590295B2 to The University of Hong Kong on March 31, 2026, granting exclusive rights to methods of using mesenchymal stromal cells as a reprogramming source for iPSC induction. The patent names five inventors including Chi-Fung Chan and Kenneth Richard Boheler, with CPC classifications in cellular therapy and stem cell technologies.

Biotechnology companies, pharmaceutical researchers, and academic institutions engaged in iPSC work should conduct freedom-to-operate analyses to determine if this patent covers their activities. Licensing negotiations may be necessary for commercial applications. No immediate compliance action is required, but this grant affects competitive positioning in the cell therapy and regenerative medicine space.